2022年免疫疗法桥梁大会（11月30日至12月1日，意大利那不勒斯）特别设立辩论环节，讨论了免疫疗法领域的三个当代热门议题。辩论包括领先专家的对立观点，涉及以下问题：细胞免疫治疗（ACT）是否在实体瘤治疗中发挥作用，癌症免疫治疗中外周/血液标志物与肿瘤微环境标志物的使用，以及嵌合抗原受体T细胞与自然杀伤细胞治疗的作用。就如同免疫疗法桥梁大会辩论的传统，演讲者应由会议主席邀请来表达所分配的辩题的一方，而表达的观点可能并不完全反映他们个人的观点。在每个辩题的辩论前后，听众都可以表决支持两种观点中的哪一种。 ©2023.作者。

The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.© 2023. The Author(s).